

Market Analysis 2020 on 38th Euro Global Summit and Expo on Vaccines & Vaccination


Catherine Heffernan

Public Health England, London, E-mail: catherine.heffernan@nhs.net

Market Analysis of Vaccines


This statistic displays the top 5 global [vaccine products](#) based on their revenues worldwide in 2014, and a projection for 2020. Pfizer's pneumococcal vaccine, Prevnar 13, is expected to generate 5.8 billion U.S. dollars in revenues by 2020. A vaccine often contains an agent that is made from a weakened form of a disease microbe, that is then used to stimulate the body's immune system to destroy and recognize the microorganism in case of later exposures.

Global Vaccines Market size was valued over USD 38.5 billion in 2018 and is projected to witness more than 9% CAGR from 2019 to 2025.



Germany vaccines market size, by technology, 2018 & 2025 (USD Million)


Global Vaccines Market, By Age Group



Market Analysis 2020 on 38th Euro Global Summit and Expo on Vaccines & Vaccination
June 08-09, 2020 | Frankfurt, Germany

Adult vaccines market will witness robust growth of more than 9.5% during the forecast period. Rising awareness about vaccine preventable diseases among adult population coupled with government's numerous efforts to increase adult immunization rate will drive the adult vaccines growth over the upcoming period. Rise in demand for vaccines against influenza, tetanus, Shingles, human papillomavirus (HPV), varicella (chicken pox) and others including Hepatitis B, meningococcus and pneumococcus vaccines among adults will elevate the business growth.


Top 5 global vaccine products based on revenue in 2014 and 2020 (in million U.S. dollars)



Top 10 pharmaceutical companies based on global vaccine revenue market share in 2014 and 2020:

This statistic displays the top 10 global pharmaceutical companies based on their vaccine revenue market share worldwide in 2014, and a projection for 2020. Pfizer is expected to account for nearly 21 percent of the global [vaccine market](#) share by 2020, largely due to success with its pneumococcal vaccine, Prevnar 13. A vaccine often

contains an agent that is made from a weakened form of a disease microbe, that is then used to stimulate the body's [immune system](#) to destroy and recognize the microorganism in case of later exposures.



Market Share

Importance and Scope:

The base year of the study is 2017, with forecast done up to 2023. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on volume shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the Global Vaccines market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the types of vaccines by technology and vaccines by disease indication.

Target Audience:

Euro Vaccines-2016 Targets, CEO's, Directors,
Scientists, Professors, Students of all Biotech &

Pharma companies, Universities and colleges globally

Top Global Immunology Universities:

- Harvard University
- University of California--San Francisco
- Stanford University
- Yale University
- Johns Hopkins University
- Washington University in St. Louis
- Duke University
- University of Pennsylvania
- University of Texas South-western Medical Center--Dallas University of California, San Francisco

Companies Associated with Vaccines

- Merck & Co.
- Abbott
- AstraZeneca
- Bristol-Myers Squibb
- Astellas Pharma
- Sanofi Pasteur
- Johnson & Johnson
- GlaxoSmithKline
- Pfizer
- Emergent BioSolutions
- Novartis